Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-8000 + pembrolizumab in advanced NSCLC
NCT05141357Phase 2Terminated
- Sponsor
- HUYABIO International, LLC
- Start
- Feb 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in non-small cell lung cancer (NSCLC), sponsored by HUYABIO International, LLC. Primary endpoint: Safety and Tolerability of HBI-8000 When Administered in Combination With Standard Dose and Regimen of Pembrolizumab. Started Feb 2022; status: terminated.
02
Drugs
tucidinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05141357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141357.